Newcastle upon Tyne
Newcastle upon Tyne
Newcastle upon Tyne, Tyne and Wear, United Kingdom38 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 3 | 2026-10-06 | NCT07284901 | |
| Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 3 | 2026-10-06 | NCT07284875 | |
| A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | Familial Primary Pulmonary Hypertension, Skin and Connective Tissue Diseases, cardiovascular disorder, connective tissue disorder, hypertensive disorder, lung disorder, pulmonary arterial hypertension, pulmonary hypertension, respiratory system disorder, vascular disorder | Enrolling by invitation | Phase 3 | 2026-10-06 | NCT03683186 | |
| Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events | Arterial Occlusive Diseases, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Atherosclerotic, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Active, not recruiting | Phase 3 | 2026-10-05 | NCT05360446 | |
| A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, autoimmune disease, chronic renal failure syndrome, glomerulonephritis, immune system disorder, kidney disorder, kidney failure, nephritis, urinary system disorder | Recruiting | Phase 3 | 2026-10-05 | NCT04557462 | |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Adnexal Diseases, Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, biliary tract disorder, breast cancer, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, gallbladder disorder, gallbladder neoplasm, gonadal disorder, head and neck cancer, intestinal disorder, lung cancer, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, metastatic malignant neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, prostate cancer, prostate disorder, rectal disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, small cell lung carcinoma, triple-negative breast carcinoma, uterine disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-02 | NCT04585750 | |
| A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder | Recruiting | Phase 2 | 2026-09-28 | NCT07217067 | |
| An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Phase 3 | 2026-09-04 | NCT07517263 | |
| A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 3 | 2026-08-26 | NCT05625399 | |
| Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 | 2026-08-25 | NCT02715284 | |
| Lion's Mane Dosing on Attention and Mood | Attention | Not yet recruiting | Not applicable | 2026-08-12 | NCT07759687 | |
| Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, complement 3 glomerulopathy, glomerulonephritis, immune system disorder, kidney disorder, membranoproliferative glomerulonephritis, nephritis, urinary system disorder | Recruiting | Phase 3 | 2026-08-07 | NCT03955445 | |
| Keep Exercising & Stay Steady: Development and Feasibility of a Health Intervention to Encourage Exercise Maintenance After Fall Prevention Exercise Programmes End. | Fall Patients | Recruiting | Not applicable | 2026-07-28 | NCT06447948 | |
| PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort | Neurologic Manifestations, Parkinson disease, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, anosmia, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Not stated | 2026-07-27 | NCT04477785 | |
| A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) | autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, primary dysautonomia, synucleinopathy | Active, not recruiting | Phase 3 | 2026-07-14 | NCT06706622 | |
| Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urination Disorders, Urogenital Diseases, Urological Manifestations, complement 3 glomerulopathy, proteinuria, urinary system disorder | Recruiting | Phase 3 | 2026-07-13 | NCT04817618 | |
| First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) | Advanced Metastatic Castration-resistant Prostate Cancer; Prostate Specific Membrane Antigen (PSMA) Expression | Recruiting | Phase 1 | 2026-07-07 | NCT06217822 | |
| A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, urinary system disorder | Active, not recruiting | Phase 1 | 2026-07-07 | NCT05614102 | |
| A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction | Left Ventricular Systolic Dysfunction, Ventricular Dysfunction, Ventricular Dysfunction, Left, cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 3 | 2026-06-29 | NCT07192952 | |
| A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction | Left Ventricular Systolic Dysfunction, Ventricular Dysfunction, Ventricular Dysfunction, Left, cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 3 | 2026-06-15 | NCT07188805 | |
| CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) | Head and Neck Neoplasms, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, neoplasm, otorhinolaryngologic disease | Active, not recruiting | Phase 3 | 2026-05-07 | NCT04116047 | |
| Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS) | Cytopenia, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Urogenital Diseases, anemia, atypical hemolytic-uremic syndrome, blood platelet disease, hematologic disorder, hemolytic anemia, hemolytic-uremic syndrome, kidney disorder, thrombocytopenia, thrombotic microangiopathy, uremia, urinary system disorder | Recruiting | Phase 3 | 2026-04-29 | NCT05935215 | |
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, epithelial neoplasm, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 3 | 2026-04-16 | NCT05580562 | |
| A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Active, not recruiting | Phase 1 / Phase 2 | 2026-04-08 | NCT04404660 | |
| Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD) | Abnormalities, Multiple, Ciliopathies, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, autosomal dominant polycystic kidney disease, cystic kidney disease, hereditary disease, kidney disorder, polycystic kidney disease, urinary system disorder | Recruiting | Phase 3 | 2026-03-31 | NCT04939935 |